Advertisement

The Additive Value of Cardiovascular Magnetic Resonance Imaging in Hypertensive Heart Disease

  • Sebastian Onciul
  • Peter Swoboda
  • Sven Plein
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Cardiovascular magnetic resonance (CMR) can provide a wealth of diagnostic information in the assessment of hypertensive heart disease (HHD) that is complementary to echocardiography. CMR assessment of left ventricular wall thickness, volumes and function is both highly accurate and reproducible and can be used to describe the pattern of ventricular remodelling in HHD. Using CMR it is possible to detect and quantify the extent of myocardial fibrosis by late gadolinium enhancement (LGE), which may inform individualized risk stratification and influence treatment strategy. T1 mapping techniques offer additional insights into the cellular and extracellular compartments, and the combined assessment of both LGE pattern and T1 mapping findings can help in the differentiation of HHD from other conditions presenting with left ventricular hypertrophy. In this chapter we discuss the additive information that CMR can provide in clinical setting as well as its contribution to determining pathophysiological mechanisms in HHD.

Keywords

Hypertension Left ventricle hypertrophy Cardiovascular magnetic resonance Myocardial fibrosis 

References

  1. 1.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.CrossRefGoogle Scholar
  2. 2.
    Swoboda PP, McDiarmid AK, Page SP, Greenwood JP, Plein S. Role of T1 mapping in inherited cardiomyopathies. Eur Cardiol. 2016;11(2):96–101.CrossRefGoogle Scholar
  3. 3.
    Rodrigues JCL, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE, Burchell AE, Hart EC, Hamilton MCK, Paton JFR, Nightingale AK, Manghat NE. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness >/= 15 mm. Eur Radiol. 2017;27(3):1125–35.CrossRefGoogle Scholar
  4. 4.
    Treibel TA, Zemrak F, Sado DM, Banypersad SM, White SK, Maestrini V, Barison A, Patel V, Herrey AS, Davies C, Caulfield MJ, Petersen SE, Moon JC. Extracellular volume quantification in isolated hypertension—changes at the detectable limits? J Cardiovasc Magn Reson. 2015;17(1):74.CrossRefGoogle Scholar
  5. 5.
    Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379(9814):453–60.CrossRefGoogle Scholar
  6. 6.
    Rodrigues JCL, Amadu AM, Dastidar AG, Szantho GV, Lyen SM, Godsave C, Ratcliffe LEK, Burchell AE, Hart EC, Hamilton MCK, Nightingale AK, Paton JFR, Manghat NE, Bucciarelli-Ducci C. Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. Heart. 2016;102(20):1671–9.CrossRefGoogle Scholar
  7. 7.
    Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein HU, Pennell DJ. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2018;90(1):29–34.CrossRefGoogle Scholar
  8. 8.
    Krittayaphong R, Boonyasirinant T, Chaithiraphan V, Maneesai A, Saiviroonporn P, Nakyen S, Thanapiboonpol P, Yindeengam A, Udompanturak S. Prognostic value of late gadolinium enhancement in hypertensive patients with known or suspected coronary artery disease. Int J Cardiovasc Imaging. 2010;26 Suppl 1:123–31.CrossRefGoogle Scholar
  9. 9.
    Maceira AM, Mohiaddin RH. Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson. 2012;14(1):28.CrossRefGoogle Scholar
  10. 10.
    Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53:284–91.CrossRefGoogle Scholar
  11. 11.
    Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89.CrossRefGoogle Scholar
  12. 12.
    Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J, Epstein FH, Kramer CM, Salerno M. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging. 2015;8(2):172–80.CrossRefGoogle Scholar
  13. 13.
    Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–44.CrossRefGoogle Scholar
  14. 14.
    Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006;21(1):20–3.CrossRefGoogle Scholar
  15. 15.
    Rathi VK, Doyle M, Yamrozik J, Williams RB, Caruppannan K, Truman C, Vido D, Biederman RWW. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach. J Cardiovasc Magn Reson. 2008;10(1):36.CrossRefGoogle Scholar
  16. 16.
    Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, Raman SV. Influence of myocardial fibrosis on left ventricular diastolic function: non-invasive assessment by CMR and ECHO. Circ Cardiovasc Imaging. 2009;2(6):437–43.CrossRefGoogle Scholar
  17. 17.
    Wang L, Jerosch-Herold M, Jacobs DR, Shahar E, Detrano R, Folsom AR. Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2006;48(5):1018–26.CrossRefGoogle Scholar
  18. 18.
    Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H, O’Mahony C, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Hasdai D, Ponikowski P, Achenbach S, Alfonso F, Basso C, Cardim NM, Gimeno JR, Heymans S, Holm PJ, Keren A, Kirchhof P, Kolh P, Lionis C, Muneretto C, Priori S, Salvador MJ, Wolpert C, Zamorano JL, Frick M, Aliyev F, Komissarova S, Mairesse G, Smajić E, Velchev V, Antoniades L, Linhart A, Bundgaard H, Heliö T, Leenhardt A, Katus HA, Efthymiadis G, Sepp R, Thor Gunnarsson G, Carasso S, Kerimkulova A, Kamzola G, Skouri H, Eldirsi G, Kavoliuniene A, Felice T, Michels M, Hermann Haugaa K, Lenarczyk R, Brito D, Apetrei E, Bokheria L, Lovic D, Hatala R, Garcia Pavía P, Eriksson M, Noble S, Srbinovska E, Özdemir M, Nesukay E, Sekhri N. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRefGoogle Scholar
  19. 19.
    Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54:220–8.CrossRefGoogle Scholar
  20. 20.
    Rodrigues JCL, Amadu AM, Dastidar AG, Hassan N, Lyen SM, Lawton CB, Ratcliffe LE, Burchell AE, Hart EC, Hamilton MCK, Paton JFR, Nightingale AK, Manghat NE. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2016;17(12):1405–13.CrossRefGoogle Scholar
  21. 21.
    Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu C-Y, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015;8(12):e003285.CrossRefGoogle Scholar
  22. 22.
    Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–93.CrossRefGoogle Scholar
  23. 23.
    Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–8.CrossRefGoogle Scholar
  24. 24.
    Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, Captur G, Anderson S, Piechnik SK, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Kellman P, Elliott PM, Herrey AS, Moon JC. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16(1):99.CrossRefGoogle Scholar
  25. 25.
    Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD, Ostman-Smith I, Casadei B, Watkins H, Neubauer S. Differentiation of athlete’s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2005;7:551–8.CrossRefGoogle Scholar
  26. 26.
    McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent DA, Dobson LE, Musa TA, Ripley DP, Garg P, Greenwood JP, Ferguson C, Plein S. Athletic cardiac adaptation in males is a consequence of elevated myocyte mass. Circ Cardiovasc Imaging. 2016;9(4):e003579.CrossRefGoogle Scholar
  27. 27.
    Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, Ferguson C, Page SP, Greenwood JP, Plein S. Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from Athlete’s heart. J Am Coll Cardiol. 2016;67:2189–90.CrossRefGoogle Scholar
  28. 28.
    Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB, Francis JM, Robson MD, Arnold JR, Mihai R, Thomas JDJ, Herincs M, Hassan-Smith ZK, Greiser A, Arlt W, Korbonits M, Karavitaki N, Grossman AB, Wass JAH, Neubauer S. Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction. J Am Coll Cardiol. 2016;67(20):2364–74.CrossRefGoogle Scholar
  29. 29.
    Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux R, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan intervention for endpoint-reduction in hypertension. Am Heart J. 2002;144:530–7.CrossRefGoogle Scholar
  30. 30.
    Doltra A, Messroghli D, Stawowy P, Hassel J-H, Gebker R, Leppanen O, Grafe M, Schneeweis C, Schnackenburg B, Fleck E, Kelle S. Potential reduction of interstitial myocardial fibrosis with renal denervation. J Am Heart Assoc. 2014;3(6):e001353.CrossRefGoogle Scholar
  31. 31.
    Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension. 2009;54:731–7.CrossRefGoogle Scholar
  32. 32.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8.CrossRefGoogle Scholar
  33. 33.
    Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, George J, Struthers AD. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284 LP–2293.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sebastian Onciul
    • 1
  • Peter Swoboda
    • 2
  • Sven Plein
    • 2
  1. 1.University of Medicine and Pharmacy Carol DavilaBucharestRomania
  2. 2.Multidisciplinary Cardiovascular Research Centre and Division of Biomedical Imaging, Leeds Institute of Cardiovascular and Metabolic MedicineUniversity of LeedsLeedsUK

Personalised recommendations